Literature DB >> 22825583

New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment.

Marc Ladanyi1, Marjorie G Zauderer, Lee M Krug, Tatsuo Ito, Robert McMillan, Matthew Bott, Filippo Giancotti.   

Abstract

Malignant pleural mesothelioma (MPM) is a highly lethal cancer with limited therapeutic options. Recent work has focused on the frequent somatic inactivation of two tumor suppressor genes in MPM-NF2 (Neurofibromatosis type 2) and the recently identified BAP1 (BRCA associated protein 1). In addition, germline mutations in BAP1 have been identified that define a new familial cancer syndrome, which includes MPM, ocular melanoma, and other cancers. These recent advances may allow screening of high-risk individuals and the development of new therapies that target key pathways in MPM. ©2012 AACR.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22825583      PMCID： PMC3432735          DOI： 10.1158/1078-0432.CCR-11-2375

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  45 in total

1.  Germline BAP1 mutations and tumor susceptibility.

Authors:  Alisa M Goldstein
Journal:  Nat Genet       Date:  2011-09-28       Impact factor: 38.330

Review 2.  Malignant mesothelioma: facts, myths, and hypotheses.

Authors:  Michele Carbone; Bevan H Ly; Ronald F Dodson; Ian Pagano; Paul T Morris; Umran A Dogan; Adi F Gazdar; Harvey I Pass; Haining Yang
Journal:  J Cell Physiol       Date:  2012-01       Impact factor: 6.384

3.  Frequent mutation of BAP1 in metastasizing uveal melanomas.

Authors:  J William Harbour; Michael D Onken; Elisha D O Roberson; Shenghui Duan; Li Cao; Lori A Worley; M Laurin Council; Katie A Matatall; Cynthia Helms; Anne M Bowcock
Journal:  Science       Date:  2010-11-04       Impact factor: 47.728

Review 4.  Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation.

Authors:  Yoshitaka Sekido
Journal:  Pathol Int       Date:  2011-05-02       Impact factor: 2.534

Review 5.  An emerging model for BAP1's role in regulating cell cycle progression.

Authors:  Ziad M Eletr; Keith D Wilkinson
Journal:  Cell Biochem Biophys       Date:  2011-06       Impact factor: 2.194

6.  The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.

Authors:  Matthew Bott; Marie Brevet; Barry S Taylor; Shigeki Shimizu; Tatsuo Ito; Lu Wang; Jenette Creaney; Richard A Lake; Maureen F Zakowski; Boris Reva; Chris Sander; Robert Delsite; Simon Powell; Qin Zhou; Ronglai Shen; Adam Olshen; Valerie Rusch; Marc Ladanyi
Journal:  Nat Genet       Date:  2011-06-05       Impact factor: 38.330

7.  Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma.

Authors:  Sheelu Varghese; Zhaorong Chen; David L Bartlett; James F Pingpank; Steven K Libutti; Seth M Steinberg; John Wunderlich; H Richard Alexander
Journal:  Cancer       Date:  2010-09-13       Impact factor: 6.860

8.  Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy.

Authors:  Marie Brevet; Shigeki Shimizu; Matthew J Bott; Neerav Shukla; Qin Zhou; Adam B Olshen; Valerie Rusch; Marc Ladanyi
Journal:  J Thorac Oncol       Date:  2011-05       Impact factor: 15.609

9.  Germline mutations in BAP1 predispose to melanocytic tumors.

Authors:  Thomas Wiesner; Anna C Obenauf; Rajmohan Murali; Isabella Fried; Klaus G Griewank; Peter Ulz; Christian Windpassinger; Werner Wackernagel; Shea Loy; Ingrid Wolf; Agnes Viale; Alex E Lash; Mono Pirun; Nicholas D Socci; Arno Rütten; Gabriele Palmedo; David Abramson; Kenneth Offit; Arthur Ott; Jürgen C Becker; Lorenzo Cerroni; Heinz Kutzner; Boris C Bastian; Michael R Speicher
Journal:  Nat Genet       Date:  2011-08-28       Impact factor: 38.330

10.  Germline BAP1 mutations predispose to malignant mesothelioma.

Authors:  Joseph R Testa; Mitchell Cheung; Jianming Pei; Jennifer E Below; Yinfei Tan; Eleonora Sementino; Nancy J Cox; A Umran Dogan; Harvey I Pass; Sandra Trusa; Mary Hesdorffer; Masaki Nasu; Amy Powers; Zeyana Rivera; Sabahattin Comertpay; Mika Tanji; Giovanni Gaudino; Haining Yang; Michele Carbone
Journal:  Nat Genet       Date:  2011-08-28       Impact factor: 38.330
View more
  27 in total

1.  Pancreatic intraductal tubulopapillary neoplasm is genetically distinct from intraductal papillary mucinous neoplasm and ductal adenocarcinoma.

Authors:  Olca Basturk; Michael F Berger; Hiroshi Yamaguchi; Volkan Adsay; Gokce Askan; Umesh K Bhanot; Ahmet Zehir; Fatima Carneiro; Seung-Mo Hong; Giuseppe Zamboni; Esra Dikoglu; Vaidehi Jobanputra; Kazimierz O Wrzeszczynski; Serdar Balci; Peter Allen; Naoki Ikari; Shoko Takeuchi; Hiroyuki Akagawa; Atsushi Kanno; Tooru Shimosegawa; Takanori Morikawa; Fuyuhiko Motoi; Michiaki Unno; Ryota Higuchi; Masakazu Yamamoto; Kyoko Shimizu; Toru Furukawa; David S Klimstra
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

2.  Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations.

Authors:  Marjorie G Zauderer; Matthew Bott; Robert McMillan; Camelia S Sima; Valerie Rusch; Lee M Krug; Marc Ladanyi
Journal:  J Thorac Oncol       Date:  2013-11       Impact factor: 15.609

Review 3.  Biology of advanced uveal melanoma and next steps for clinical therapeutics.

Authors:  Jason J Luke; Pierre L Triozzi; Kyle C McKenna; Erwin G Van Meir; Jeffrey E Gershenwald; Boris C Bastian; J Silvio Gutkind; Anne M Bowcock; Howard Z Streicher; Poulam M Patel; Takami Sato; Jeffery A Sossman; Mario Sznol; Jack Welch; Magdalena Thurin; Sara Selig; Keith T Flaherty; Richard D Carvajal
Journal:  Pigment Cell Melanoma Res       Date:  2014-09-01       Impact factor: 4.693

4.  Prognostic role of BAP1 in pT1 clear cell carcinoma in partial nephrectomy specimens.

Authors:  Daniele Minardi; Guendalina Lucarini; Giulio Milanese; Rodolfo Montironi; Roberto Di Primio
Journal:  Virchows Arch       Date:  2017-05-09       Impact factor: 4.064

5.  A new standard for malignant pleural mesothelioma.

Authors:  Marjorie G Zauderer
Journal:  Lancet       Date:  2015-12-21       Impact factor: 79.321

6.  Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis.

Authors:  Jonathan Cooper; Qingwen Xu; Lu Zhou; Milica Pavlovic; Virginia Ojeda; Kamalika Moulick; Elisa de Stanchina; John T Poirier; Marjorie Zauderer; Charles M Rudin; Matthias A Karajannis; C Oliver Hanemann; Filippo G Giancotti
Journal:  Mol Cancer Ther       Date:  2017-05-03       Impact factor: 6.261

7.  PBRM1 and BAP1 as novel targets for renal cell carcinoma.

Authors:  James Brugarolas
Journal:  Cancer J       Date:  2013 Jul-Aug       Impact factor: 3.360

8.  BAP1 protein is a progression factor in malignant pleural mesothelioma.

Authors:  Lisa Arzt; Franz Quehenberger; Iris Halbwedl; Thomas Mairinger; Helmut H Popper
Journal:  Pathol Oncol Res       Date:  2013-08-22       Impact factor: 3.201

Review 9.  Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies.

Authors:  Angela Bononi; Andrea Napolitano; Harvey I Pass; Haining Yang; Michele Carbone
Journal:  Expert Rev Respir Med       Date:  2015-08-26       Impact factor: 3.772

Review 10.  New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas.

Authors:  Brooke T Mossman; Arti Shukla; Nicholas H Heintz; Claire F Verschraegen; Anish Thomas; Raffit Hassan
Journal:  Am J Pathol       Date:  2013-02-08       Impact factor: 4.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.